Gondko Daniel, Dębiec Patrycja, Roman Jakub, Pietrzak Nikodem, Kocot Krzysztof, Kusa Jacek
Department and Clinic of Pediatric Cardiology, Medical University of Silesia in Katowice, Katowice, Poland.
Cardiol J. 2025;32(2):175-188. doi: 10.5603/cj.99070. Epub 2025 Feb 25.
Galectin-3 (Gal-3), a β-galactoside-binding lectin, has emerged as a potential diagnostic and prognostic biomarker for various diseases, including certain heart and kidney diseases, as well as cancer. Its significance is particularly notable in the context of congenital heart defects (CHD), which are the most prevalent congenital malformations, occurring in 6 to 8 out of every 1000 live births. Symptoms of heart failure (HF) in patients with congenital heart defects can manifest early in life, but in some cases, the disease progresses gradually, leading to a gradual decline in quality of life and the development of various complications. This variability underscores the need for early biomarkers to detect HF development in pediatric patients. Gal-3 plays a key role in myocardial remodeling, making it a promising candidate for advancing the diagnosis and management of HF in CHD patients. It is especially relevant in pediatric care, where early detection and intervention can significantly alter disease progression and patient outcomes. This review aims to consolidate current knowledge on the utility of Gal-3 in predicting HF among pediatric patients with CHD, highlighting its potential in changing the direction of diagnosis and treatment in this vulnerable patient population.
半乳糖凝集素-3（Gal-3）是一种β-半乳糖苷结合凝集素，已成为包括某些心脏和肾脏疾病以及癌症在内的多种疾病的潜在诊断和预后生物标志物。其在先天性心脏病（CHD）中的意义尤为显著，先天性心脏病是最常见的先天性畸形，每1000例活产中就有6至8例发生。先天性心脏病患者的心力衰竭（HF）症状可能在生命早期出现，但在某些情况下，疾病会逐渐进展，导致生活质量逐渐下降并出现各种并发症。这种变异性凸显了需要早期生物标志物来检测儿科患者心力衰竭的发展。Gal-3在心肌重塑中起关键作用，使其成为推进先天性心脏病患者心力衰竭诊断和管理的有希望的候选者。它在儿科护理中尤为重要，早期检测和干预可显著改变疾病进展和患者预后。本综述旨在巩固目前关于Gal-3在预测先天性心脏病儿科患者心力衰竭方面效用的知识，强调其在改变这一脆弱患者群体诊断和治疗方向方面的潜力。
